Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

GYKI 52895

From Wikipedia, the free encyclopedia
(Redirected fromGYKI-52895)
Chemical compound
Pharmaceutical compound
GYKI 52895
Clinical data
Other names4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine
Identifiers
  • 4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H17N3O2
Molar mass295.342 g·mol−1
3D model (JSmol)
  • O1c2c(OC1)cc3c(c2)C(=N/NC(C3)C)\c4ccc(N)cc4
  • InChI=1S/C17H17N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8,10,19H,6,9,18H2,1H3 checkY
  • Key:AQTITSBNGSVQNZ-UHFFFAOYSA-N checkY
  (verify)

GYKI 52895 is a drug which is a 2,3-benzodiazepine derivative that also shares the3,4-methylenedioxyamphetaminepharmacophore. Unlike other similar drugs, GYKI 52895 is a selectivedopamine reuptake inhibitor (DRI),[1][2] which appears to have an atypical mode of action compared to other DRIs.[3] Its DRI activity is shared by numerous addictive drugs includingamphetamine and its derivatives (e.g.dextromethamphetamine),cocaine, andmethylphenidate and its derivatives (e.g.ethylphenidate). However, dopaminergic drugs are also prone to producingemetic effects such as in the case ofapomorphine.

Egis Pharmaceuticals began clinical development of the drug in 1997 formajor depressive disorder andParkinson's disease, but it was discontinued in 2001.[4]

See also

[edit]

References

[edit]
  1. ^Horváth K, Szabó H, Pátfalusi M, Berzsenyi P, Andrási F (1990). "Pharmacological Effects of GYKI 52895, a New Selective Dopamine Uptake Inhibitor".European Journal of Pharmacology.183 (4):1416–1417.doi:10.1016/0014-2999(90)94548-C.
  2. ^Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, et al. (June 1999)."Modulation of dopamine transporter activity by nicotinic acetylcholine receptors and membrane depolarization in rat pheochromocytoma PC12 cells".Journal of Neurochemistry.72 (6):2437–44.doi:10.1046/j.1471-4159.1999.0722437.x.PMID 10349853.
  3. ^Vaarmann A, Gandhi S, Gourine AV, Abramov AY (2010). "Novel pathway for an old neurotransmitter: dopamine-induced neuronal calcium signalling via receptor-independent mechanisms".Cell Calcium.48 (2–3):176–82.doi:10.1016/j.ceca.2010.08.008.PMID 20846720.
  4. ^"GYKI 52895". Adis Insight.
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
1,4-Benzodiazepines
1,5-Benzodiazepines
2,3-Benzodiazepines*
Triazolobenzodiazepines
Imidazobenzodiazepines
Oxazolobenzodiazepines
Thienodiazepines
Thienotriazolodiazepines
Thienobenzodiazepines*
Pyridodiazepines
Pyridotriazolodiazepines
Pyrazolodiazepines
Pyrrolodiazepines
Tetrahydroisoquinobenzodiazepines
Pyrrolobenzodiazepines*
Benzodiazepine prodrugs
* atypical activity profile (notGABAA receptor ligands)
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=GYKI_52895&oldid=1307941848"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp